NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
OPTH
Optimi Health Corp.
There isn't enough reported data to score OPTH yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OPTH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
OPTH's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OPTH PE Valuation
OPTH has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OPTH Forward outlook
There aren't enough analyst estimates for OPTH to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus OPTH down 205%.
OPTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2023 | -$1.31 | +$1.32 |
| Q1 2023 | -$1.31 | +$1.61 |
| Q4 2022 | -$1.55 | +$1.18 |
| Q3 2022 | -$2.12 | +$0.02 |
OPTH is still losing money, but far less than before: $1.37 per share over the past year, against $2.92 at its worst in early 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over OPTH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OPTH on profitability, with a higher operating margin.
OPTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $98.7K | -29% |
| Q1 2026 | $70K | +62% |
| Q2 2025 | $138.1K | +58% |
| Q1 2025 | $43.1K | -26% |
| Q4 2024 | $163.6K | +121% |
| Q3 2024 | $40.7K | +190% |
| Q2 2024 | $87.2K | +185% |
| Q1 2024 | $58.3K | +18% |
OPTH's revenue has slid since its 2024 peak: $98,700 last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1523% | -1116 points |
| Q1 2026 | -1364% | +251 points |
| Q2 2025 | -406% | +445 points |
| Q1 2025 | -1615% | +11 points |
| Q4 2024 | -498% | +602 points |
| Q3 2024 | -2744% | +3779 points |
| Q2 2024 | -851% | +2101 points |
| Q1 2024 | -1626% | -1626 points |
OPTH's operating margin was −1523% last quarter, down 1025 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over OPTH on cash generation, producing positive trailing cash flow while its opponent burns cash.
OPTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | -$1.4M |
| Q1 2026 | -$242.3K | -$188.7K |
| Q4 2025 | -$449.9K | -$217.4K |
| Q3 2025 | -$1M | -$462.4K |
| Q2 2025 | -$603.5K | +$137K |
| Q1 2025 | -$53.6K | +$472.8K |
| Q4 2024 | -$232.5K | +$1.1M |
| Q3 2024 | -$557.6K | +$363.3K |
OPTH has burned cash in almost every quarter: −$4M over the past year, against −$1M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over OPTH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OPTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +33% | +1.1M shares |
| 1 year | +33% | +1.1M shares |
| 3 years | +84% | +2M shares |
OPTH has 4M diluted shares, up 33% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OPTH hasn't bought back shares in the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OPTH Net Leverage
OPTH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OPTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.5 | Oversold |
| Stochastic | 11.4 | Oversold |
OPTH's weekly RSI is 27 (oversold) and its Stochastic is 11 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OPTH PE vs Healthcare Sector
OPTH has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has stronger trend alignment. NVO is above 1 of 5 weekly averages versus OPTH above 0 of 4.
OPTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 35% below |
| 20 week MA | $4.24 | 49% below |
| 50 week MA | $5.63 | 61% below |
| 100 week MA | $5.22 | 58% below |
OPTH is in a downtrend: it's below all four of its weekly moving averages, and 58% below its 100-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over OPTH on returns for 2026, with the stronger performance.
OPTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $7.20 | $4.70 | -35% |
| 2025 | $4.70 | $7.26 | +54% |
| 2026 YTD | $7.26 | $2.18 | -70% |
OPTH has finished lower in one of the last two years. It's down 70% so far in 2026.